Teva Canada Limited, headquartered in Toronto, is part of Teva Pharmaceutical Industries Ltd., the world’s largest generic drug maker. We’re proud to have been part of Canadian healthcare for more than 50 years, to market more than 400 medications across the country and to employ more than 1,000 Canadians. If you’re looking for information about our company, please contact Public Affairs at Teva Canada Limited at Public.Affairs@tevacanada.com
Latest news from Teva Canada
Teva Canada Limited is voluntarily recalling EquateTM Lens Care System 360 mL bottle and EquateTM Multi-Purpose Solution 355 mL bottle with the lot number 150261 (December 17, 2018).
Teva Canada Limited is voluntarily recalling Novamoxin 125 mg/5 mL (100 mL) and Novamoxin 250 mg/5 mL (75 mL) Granules For Oral Suspension, with the lot numbers 35438292B, 35438811A and 35439807A (November 23, 2018).
Teva Canada Limited is voluntarily recalling ACT Candesartan 4 mg tablets, with the lot numbers K49247, K49268, K49269, K50970, K50973 and K51008 (November 23, 2018).
Teva Canada Announces the Launch of a Generic Version of PrAbilify®, PrTeva-Aripiprazole Tablets for the treatment of Schizophrenia (September 10, 2018).
Canadian pharmacists are becoming vaccine providers in their communities (July 27, 2018)
View our global media page for news from Teva around the world.